• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

M&A Analysis: 10 Reasons Why ResMed Acquired Propeller Health for $225M

by Fred Pennic 12/12/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

M&A Analysis: 10 Reasons Why ResMed Acquired Propeller Health for $225M

On December 3rd, ResMed announced the acquisition of digital therapeutics maker Propeller Health for $225 million to help establish itself as a leader in COPD management across all stages of the disease. Digital medicines can help to personalize treatments, monitor patients in real-time, detect day-to-day changes in disease condition and increase patient adherence.

Founded in 2010, Propeller helps people and their doctors better manage their COPD and asthma. Propeller’s digital medicine platform consists of small sensors that easily attach to consumers’ inhalers and pair with a mobile app to automatically track medication use and provide personal feedback and insights.

Propeller’s clinically validated solutions have demonstrated a 58 percent improvement in medication adherence, a 48 percent increase in symptom-free days and a 53 percent reduction in emergency room visits. Propeller’s ability to support people in stage II and III severity levels of their COPD are complementary to ResMed’s own suite of cloud-connected ventilators for those with stage III and IV COPD, including Astral, Stellar and AirCurve 10 ST-A with iVAPS – plus ResMed’s new portable oxygen concentrator Mobi.

Respiratory Care Market Infancy

M&A Analysis: 10 Reasons Why ResMed Acquired Propeller Health for $225M

According to recent Ressearch2Guidance analysis, the market that Propeller Health operates in is still a niche and lags three years behind other digital segments that focus on chronic conditions (e.g. diabetes). ResMed announced that it was interested not only in augmenting their mainstream business with Propeller Health’s digital medication adherence solutions but also in stepping into Propeller Health’s established partnerships with pharma, healthcare, and payor organizations.

Why the Propeller Health Acquisition Is Good for ResMed

Ressearch2Guidance outlined ten reasons why this deal will turn out to be a good investment for ResMed divided into market-related and those relating to the company’s position within the digital respiratory market:

Market arguments:

1. An enormous addressable market: Asthma and COPD are one of the most dangerous epidemics, which affect both developed and developing economies.

According to WHO, asthma and COPD affect more than 334 million and 250 million people worldwide correspondingly. Moreover, the prevalence of both conditions is expected to increase due to demographic, social, and behavioral factors.

2. Big digital opportunity: Digital respiratory solutions could target more than 270 million patients by 2023. 

The increase in the prevalence of both major chronic conditions is set to drive the global digital respiratory opportunity, i.e. the total number of diagnosed patients with a capable mobile device that can provide access to digital services. The global digital asthma opportunity will increase to 152 million people, whereas the global digital COPD opportunity will grow to 121 million people by the end of 2023 (Digital Respiratory Report, Research2Guidance 2019).

3. The high lifetime value of asthma and COPD patients. 

The lifetime value varies from country to country. In the USA, the lifetime value of a COPD patient is estimated at US$ 200,000, whereas the lifetime value of an average asthma patient can be three times as big due to higher life expectancy. Digital solutions are expected to capture parts of these lifespan revenue streams.

4. The revenue opportunity for pharma companies. 

Digital respiratory solutions promise to improve patient’s medication adherence. The market for asthma and COPD related drugs is a multi-billion USD market reaching more than US$ 42B in 2018. Any improvement of medical adherence will have a direct impact on pharma’s revenues. 

Propeller Health’s market position:

5. The impressive network of industry partnerships that Propeller Health has built during its 8-year market life.

Starting from 2013, Propeller Health has established partnerships with Boehringer Ingelheim (2013), GSK (December 2015), Aptar Pharma (February 2016), Vectura (May 2016), Novartis (February 2017). Apart from pharma and generic drug manufacturers, Propeller Health has succeeded in reaching other major stakeholders. All in all, the company claims to have established 65 commercial programs with pharmaceutical companies, pharmacy benefit managers and healthcare systems.

6. The global presence: The company’s programs have reached several thousands of patients across sixteen countries.

7. The extensive coverage of the available device-drug combinations. 

As Propeller Health has the highest number of partnerships with pharma, their add-on inhaler sensors cover nearly 90% of the currently available types of inhalers. Due to the partnership with GSK, Propeller Health’s portfolio includes such the world’s top inhaled corticosteroid drugs as Advair and Flovent.

8. The substantial clinical evidence, proven patient outcomes, and a wide portfolio of FDA clearances. 

Having received nine FDA clearances, Propeller Health has demonstrated clinical outcomes in 15 peer-reviewed studies. The company reported a 58% increase in medication adherence, a 79% reduction in rescue inhaler use, a 63% increase in asthma control, etc.

9. An outstanding market position in the digital respiratory market. 

Although hundreds of digital respiratory solutions are available globally, Propeller Health’s width and quality of service offering, as well as its partnership ecosystem, are outstanding.

10. Availability of SaaS services and the opportunity to roll out a full-fledged patient monitoring solution. 

Apart from connected inhalers, Propeller Health offers an additional cloud-based patient management platform, which allows the company to decrease its dependency on device sales and create more value via SaaS business models.

Untapped Potential of Digital Respiratory Market

 

ResMed’s acquisition of Propeller Health illustrates the untapped potential of the emerging digital respiratory market. Connected inhaler solutions will continue to stimulate the emergence and development of a more complex ecosystem, which will include other value-adding services, result in new business models, and eventually generate the revenue streams. 

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: asthma health app, connected health, COPD, Digital Therapeutics, Healthcare Mergers & Acquisitions, Remote Patient Care, remote patient monitoring

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |